Cytokinetics Investors Urged to Seek Counsel Before Nov. 17 Lead-Plaintiff Deadline in Aficamten Case

Overview

• A securities class action has been filed for investors who bought Cytokinetics shares between December 27, 2023 and May 6, 2025.
• Complaints allege the company pointed to a September 26, 2025 PDUFA date and projected second-half 2025 approval while not disclosing that no REMS had been submitted.
• A May 6, 2025 earnings call detailed multiple pre-NDA FDA meetings and the decision to file without a REMS, relying on labeling and education materials.
• Investors seeking to lead the case must move by November 17, 2025, and no class has been certified to date.
• Robbins LLP and Rosen Law Firm are soliciting shareholders on a contingency-fee basis with no out-of-pocket costs.